You are here

Our science / Clinical Trials / Find a Trial / NCT00406952

Study for Evaluating Different Methods of Measuring Depression Treatment Response

Back to Search Print Save as PDF Bookmark Trial

NCT00406952

Last updated on December 5, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Norwich, Connecticut, 06360 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Primary diagnosis of Major Depressive Disorder with symptoms of depression present at
least 1 month

- Psychotropic medications currently not being taken

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Failure to respond in past 5 years to antidepressant therapy of adequate duration and
dosing

- Diagnoses of following conditions or disorders within past 6 months: generalized
anxiety, obsessive compulsive, panic, post stress, anorexia, bulimia, alcohol or
substance abuse or social anxiety disorder

- Diagnoses current or past of the following conditions or disorders: schizophrenia,
psychotic disorder, delieium, dememtia, amnestic cognitive disorder, bipolar

NCT00406952
Pfizer
Completed
Study for Evaluating Different Methods of Measuring Depression Treatment Response

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Epilepsy, Partial Seizure Disorder, Partial Epilepsies, Complex Partial Seizure Disorder
Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00537940
All Genders
18+
Years
Multiple Sites
Major Depressive Disorder
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
NCT00831415
All Genders
20+
Years
Multiple Sites
Bipolar Disorder
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
NCT03768726
All Genders
Panic Disorder
Study Evaluating Venlafaxine ER in Adults With Panic Disorder
NCT00038896
All Genders
Study for Evaluating Different Methods of Measuring Depression Treatment Response
A Phase 4 Randomized, Double-Blind, Placebo Controlled Methodology Study to Evaluate the Time of Onset of AntiDepressant Response in Subjects With Major Depressive Disorder
Purpose of the study is to evaluate use of electronic diaries and voice acoustics for use in future depression clinical trial. Focus is on increased precision of measurement.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Depressive Disorder, Major
  • Procedure: electronic diary
  • Drug: Sertraline
  • Drug: Placebo
  • Procedure: voice acoustics
Not Provided
Mundt JC, Vogel AP, Feltner DE, Lenderking WR. Vocal acoustic biomarkers of depression severity and treatment response. Biol Psychiatry. 2012 Oct 1;72(7):580-7. doi: 10.1016/j.biopsych.2012.03.015. Epub 2012 Apr 26.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
165
August 2007
Not Provided

Inclusion Criteria:

  • Primary diagnosis of Major Depressive Disorder with symptoms of depression present at least 1 month
  • Psychotropic medications currently not being taken

Exclusion Criteria:

  • Failure to respond in past 5 years to antidepressant therapy of adequate duration and dosing
  • Diagnoses of following conditions or disorders within past 6 months: generalized anxiety, obsessive compulsive, panic, post stress, anorexia, bulimia, alcohol or substance abuse or social anxiety disorder
  • Diagnoses current or past of the following conditions or disorders: schizophrenia, psychotic disorder, delieium, dememtia, amnestic cognitive disorder, bipolar
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00406952
A9001337
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now